Veeva Systems (VEEV) Stock
Cloud software platform for life sciences companies. Here's the price, business snapshot, and what's worth knowing about Veeva Systems in August 2026.
Veeva Systems (VEEV) is a cloud‑software company focused on the life sciences industry, providing CRM, clinical, regulatory, quality and data platforms designed for pharmaceutical, biotech and medical‑device firms. It operates a subscription‑based model with high recurring revenue, which has supported steady margins and cash generation as the sector digitises. Key growth drivers include continued R&D outsourcing, regulatory complexity that favours specialised vendors, international expansion and cross‑selling of new modules to existing customers. Investors should note Veeva’s exposure to the healthcare sector and customer concentration in large pharma, which can amplify cyclicality. The shares currently reflect a premium for software‑like margins and growth; valuation and future revenue growth are important to watch. This is general information, not personal financial advice — returns can be volatile and past performance is not a guarantee. Consider whether the company’s sector concentration and valuation fit your risk tolerance and investment horizon.
Why It’s Moving
Veeva is climbing on analyst upgrades, a major Eli Lilly CRM win, and a high-stakes earnings setup.
- Analyst upgrades and higher valuation calls have been the main catalyst, with several firms recently lifting their outlooks on Veeva as investors grow more confident in its growth and margin profile.
- Veeva secured a global commitment from Eli Lilly for its Vault CRM platform, reinforcing demand for its life sciences software suite and signaling deeper enterprise adoption.
- The stock is heading into its August 26 earnings report with expectations elevated, and recent commentary has focused on billings, revenue growth, and whether recent product wins can support the next leg higher.
Veeva is climbing on analyst upgrades, a major Eli Lilly CRM win, and a high-stakes earnings setup.
- Analyst upgrades and higher valuation calls have been the main catalyst, with several firms recently lifting their outlooks on Veeva as investors grow more confident in its growth and margin profile.
- Veeva secured a global commitment from Eli Lilly for its Vault CRM platform, reinforcing demand for its life sciences software suite and signaling deeper enterprise adoption.
- The stock is heading into its August 26 earnings report with expectations elevated, and recent commentary has focused on billings, revenue growth, and whether recent product wins can support the next leg higher.
Sixth Month Growth Performance
next-earnings-question
The next VEEV earnings date is August 26, 2026, and it is expected to be reported after the market closes. This update will cover Veeva Systems’ fiscal second quarter of 2027, ending July 31, 2026. That timing is consistent with the company’s usual late-August reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veeva Systems' stock, indicating it may increase from its current price.
Financial Health
Veeva Systems is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue model
Subscription contracts create predictable revenue and strong margins, though future growth depends on new customer wins and cross‑selling to existing clients.
Global pharma footprint
Veeva benefits from long relationships with major pharmaceutical companies and international expansion, but customer concentration can increase sector sensitivity.
Product innovation focus
Ongoing investment in specialised modules and data services supports cross‑sell opportunities, though competition and regulatory changes can affect adoption rates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
